The symptom profiles of different neurodegenerative diseases often overlap, and diagnosing age-related cognitive symptoms is complex. A patient may have multiple overlapping disease processes in the ...

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects neurons in the brain and spinal cord causing loss of muscle control. Scientists have now suggested a potential ...

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive, invariably fatal neurological disease. Individuals affected by ALS include those living with ALS, their caregivers, presymptomatic ...

ALS is characterized by the death of motor neurons, leading to progressive muscle weakness and loss of voluntary movement. Sporadic ALS accounts for approximately 90-95% of cases, while familial ALS ...

Amyotrophic lateral sclerosis (ALS) is a widespread neurodegenerative disease caused by the loss of neurons that control movement. Although abnormal accumulation of proteins called TDP-43 accompanies ...

A neurologist and a multidisciplinary team are required for the management of ALS. Whenever possible, primary care clinicians should refer the patient to a specialized ALS clinic. Treatments to manage ...

A new treatment for amyotrophic lateral sclerosis, or ALS, has been approved by the US Food and Drug Administration. The FDA announced approval of Relyvrio, developed by Amylyx Pharmaceuticals, on ...

Despite anecdotal reports of exceptional cases, ALS is a condition with relentless progression, and riluzole, the single disease-modifying drug licensed for the condition, provides only an ...

KOANEWA is a first-in-human, open-label Phase 1b clinical trial, designed to evaluate the safety and tolerability of a single administration of CTx1000 in participants with ALS [ClinicalTrials.gov].

The CURE-ND initiative was created in 2020 as a strategic partnership across leading European research institutes. CURE-ND brings together four leading national institutes (the Deutsches Zentrum für ...